A better platinum-based anticancer drug yet to come?

Area of Science:

• Oncology
• Medicinal Chemistry
• Pharmacology

Background:

• Platinum-based chemotherapy, including cisplatin, carboplatin, and oxaliplatin, faces limitations such as toxicity, drug resistance, and poor bioavailability.
• Recent advancements include next-generation drugs like satraplatin, picoplatin, and multinuclear complexes (e.g., BBR3464/triplatin), yet clinical outcomes have been disappointing.

Purpose of the Study:

• To analyze the reasons for the limited clinical success of novel platinum-based anticancer drugs.
• To identify key areas for future research and development to improve the efficacy of platinum compounds.

Main Methods:

• Review and critical analysis of preclinical and clinical data for platinum-based drugs.
• Evaluation of current drug design rationales and predictive power of preclinical assays.
• Identification of critical factors influencing platinum drug activity in vivo.

Main Results:

• Preclinical results often fail to predict clinical efficacy due to biased drug design and inadequate testing models.
• Limited tumor tissue diffusion and a lack of understanding of in vivo mechanisms (active species, transport, resistance) hinder treatment.
• Current preclinical assays may lack the predictive power needed for successful clinical translation.

Conclusions:

• Further investigation into in vivo mechanisms, including drug species, transport, and resistance, is essential.
• Development of more predictive preclinical models (resistant cell lines, spheroids, orthotopic xenografts) is required.
• Novel pharmaceutical formulations and bifunctional complexes, guided by improved preclinical selection, may yield effective platinum drugs for resistant cancers.